Morning Immunotherapy Doubles Survival Time in Lung Cancer Trial
A phase 3 trial finds scheduling immunochemotherapy before 3 PM nearly doubles progression-free and overall survival in NSCLC patients.
484 articles in this topic
A phase 3 trial finds scheduling immunochemotherapy before 3 PM nearly doubles progression-free and overall survival in NSCLC patients.
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
Regeneron's bispecific antibody linvoseltamab earns EU approval for relapsed/refractory multiple myeloma after at least three prior therapies.
A CRISPR screen reveals STK40 suppresses anti-tumor immunity in liver cancer — blocking it supercharges immunotherapy response.
A counterintuitive mechanism shows that more NECTIN4 antigen on tumor cells can actually blunt antibody-drug conjugate therapy.
Tumor-infiltrating adipocytes release a lipid metabolite that triggers neutrophil cell death, suppressing CD8+ T cells in pancreatic cancer.
A Nature Medicine study finds pathogenic germline variants in pediatric patients signal elevated cancer risk, reshaping early genetic screening protocols.
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
Circulating tumor DNA testing alongside primary treatment may sharpen prognosis for men with metastatic prostate cancer.
CRC cells exploit a heme-SDH-CoQ axis to neutralize iron-induced oxidative stress, revealing new therapeutic targets.
A phase trial finds paricalcitol safely remodels the tumor microenvironment in metastatic pancreatic cancer, boosting immune cell infiltration.
Removing dietary copper starves leukemia cells of nucleotide building blocks, boosting methotrexate efficacy against hard-to-treat CNS disease.